Incidence of acute ischemic stroke after COVID-19 or influenza among older adults, findings from PCORnet and HealthVerity, 2022

Publication date: Dec 20, 2024

Background: Although COVID-19 is a known risk factor for thrombotic conditions including embolism, stroke, and myocardial infarction, stroke incidence after implementation of thromboprophylaxis during COVID-19 hospitalization in 2021 and how incidence may differ from influenza is unknown. Methods: PCORnet and HealthVerity (HV) data assets were used to identify patients aged [≥]65 years with no prior stroke and COVID-19 or influenza during January 1-December 31, 2022, and AIS from 3 days before to 28 days after COVID-19 or influenza diagnosis. Overall demographic information (age [for HV], sex, race/ethnicity), underlying conditions, level of care, outcomes, and incidence were described and compared between those with early (-3 to 7 days from diagnosis date) and late (8 to 28 days) AIS. Results: Among 245,352 (PC) and 639,396 (HV) patients aged [≥]65 years with COVID-19, the incidence of ischemic stroke in the 3 days prior to 7 days after diagnosis of COVID-19 (PC: 962/100,000 and HV: 447/100,000) and influenza (PC: 589/100,000 and HV: 387/100,000) was significantly higher than in the 8 to 28 days after diagnosis (COVID PC: 81/100,000 and HV: 141/100,000)(influenza PC:75/100,000 and HV: 15/100,000)(all P

PDF

Concepts Keywords
100000influenza Atlanta
Influenza Cdc
Texas Copyright
Therapy Covid
Days
Diagnosis
Incidence
Influenza
Ischemic
License
Medrxiv
Pc
Phd
Preprint
Stroke

Semantics

Type Source Name
disease MESH acute ischemic stroke
disease MESH COVID-19
disease MESH influenza
disease MESH embolism
disease MESH stroke
disease MESH myocardial infarction
drug DRUGBANK Methylphenidate
disease MESH Respiratory Diseases
drug DRUGBANK Acetylsalicylic acid
drug DRUGBANK Oxygen
disease MESH Death
drug DRUGBANK Oseltamivir

Download Document

(Visited 1 times, 1 visits today)